Press Release

Article

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

Key Takeaways

  • Dana-Farber/Boston Children's is ranked #2 in pediatric cancer programs by U.S. News for 2024-25, maintaining a top-three position since 2007.
  • The center's success is due to its dedicated staff and collaboration between Dana-Farber Cancer Institute and Boston Children's Hospital.
SHOW MORE

U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation.

Scott A. Armstrong, MD, PhD

Scott A. Armstrong, MD, PhD

U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception in 2007.

"We are honored that U.S. News & World Report has recognized our program among the top pediatric cancer programs in the country and as the top program in New England for the past 18 years, and we are proud to continue providing exceptional patient care and conducting impactful research," said Scott A. Armstrong, MD, PhD, President of Dana-Farber/Boston Children's.

Andrew E. Place, MD, PhD, Vice President, Pediatric Chief Medical Officer of Dana-Farber/Boston Children's Cancer and Blood Disorders Center said, "This success is a testament to our dedicated doctors, nurses, and workforce who provide exceptional clinical care and world-class research that is changing how we treat children and adolescents with cancer."

Dana-Farber/Boston Children's brings together two internationally recognized research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care and surgery at Boston Children's and most outpatient care at Dana-Farber Cancer Institute.

David A. Williams, MD, Chief, Division of Hematology/Oncology, Boston Children's Hospital, and Leland Fikes Professor of Pediatrics at Harvard Medical School said, "The program at Dana-Farber/Boston Children's is unique, as it brings together the expertise of a world-class cancer center and an internationally renowned children's hospital to provide specialized care to children affected by cancer and blood disorders. This ranking recognizes the personalized treatment approaches we are able to deliver to all our patients."

U.S. News, together with RTI International, a North Carolina-based research and consulting firm, collected and analyzed data from 108 children's hospitals and surveyed thousands of pediatric specialists. Children's hospitals awarded a "Best" designation excelled at factors such as clinical outcomes, level and quality of hospital resources directly related to patient care, and expert opinion among pediatric specialists.

"U.S. News & World Report's annual Best Children's Hospitals evaluation empowers parents and caregivers with a data-driven guide to help them find the best pediatric hospital to treat their child," said Ben Harder, chief of health analysis and managing editor at U.S. News.

The full rankings for the 2024-25 Best Children's Hospitals Honor Roll, regional and specialty rankings can be found at USNews.com. For more information, explore #BestChildrensHospitals on Facebook, Instagram, TikTok and X.

Related Videos
Guru P. Sonpavde, MD
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Marc Machaalani, MD
Kimmie Ng, MD, MPH
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Kimmie Ng, MD, MPH
Ann H. Partridge, MD, MPH